Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced HR+/HER2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05505175
What this trial is testing

Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

Who this might be right for
Breast CancerBreast Carcinoma
Pfizer 121
Large-scale testing (Phase 3)Study completedNCT05054751
What this trial is testing

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Genor Biopharma Co., Ltd. 275
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07706179
What this trial is testing

Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer

Who this might be right for
HR+/HER2+ Breast CancerMetastatic Breast Cancer
University of Wisconsin, Madison 10
Testing effectiveness (Phase 2)Looking for participantsNCT07285382
What this trial is testing

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
HR Positive HER2 Negative Advanced Breast Cancer
wanghaibo 120
Large-scale testing (Phase 3)Study completedNCT02941926
What this trial is testing

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 3,246
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07795424
What this trial is testing

Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer

Who this might be right for
Breast CancerHR Positive, HER2 Positive Breast Cancer
Shengjing Hospital 33
Not applicableStudy completedNCT03956654
What this trial is testing

A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer

Who this might be right for
Breast Cancer
Universitaire Ziekenhuizen KU Leuven 78
Early research (Phase 1)Active Not RecruitingNCT05266105
What this trial is testing

Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Olema Pharmaceuticals, Inc. 60
Testing effectiveness (Phase 2)Looking for participantsNCT05594095
What this trial is testing

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Who this might be right for
Breast NeoplasmBreast CancerHormone Receptor Positive Tumor+2 more
Fudan University 620
Not applicableStudy completedNCT04916509
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Who this might be right for
Breast Neoplasms
Pfizer 258
Early research (Phase 1)Study completedNCT02791334
What this trial is testing

Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Who this might be right for
Solid TumorMicrosatellite Instability-High (MSI-H) Solid TumorsCutaneous Melanoma+2 more
Eli Lilly and Company 164
Early research (Phase 1)Active Not RecruitingNCT07557004
What this trial is testing

SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

Who this might be right for
HR+ / HER2- Advanced Breast Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625
What this trial is testing

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Who this might be right for
Untreated Early-stage or Locally Advanced Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105632
What this trial is testing

Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Who this might be right for
Advanced or Metastatic Breast Cancer
Pfizer 333
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06556862
What this trial is testing

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Who this might be right for
HR+/HER2- Advanced Breast Cancer
Beijing 302 Hospital 155
Testing effectiveness (Phase 2)Active Not RecruitingNCT04215146
What this trial is testing

Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Who this might be right for
Breast Cancer Metastatic
Oncolytics Biotech 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT06957379
What this trial is testing

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Who this might be right for
HR+/HER2- Advanced/Metastatic Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 78
Not applicableStudy completedNCT04394247
What this trial is testing

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

Who this might be right for
Breast Cancer
Pfizer 242
Testing effectiveness (Phase 2)Ended earlyNCT03322215
What this trial is testing

HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

Who this might be right for
Breast Cancer Metastatic
Theodoros Foukakis 42
Testing effectiveness (Phase 2)Study completedNCT05520723
What this trial is testing

Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

Who this might be right for
Triple Negative Breast CancerBreast CancerAdvanced HR+/HER2- Breast Cancer
MedSIR 50
Next Page